9015

Five-year results confirm Roches Polivy combination therapy as new standard of care for previously untreated aggressive lymphoma

Exploratory long-term follow-up analysis of the phase III POLARIX study indicated a positive trend in overall survival in favour of…

3 days ago

Roche enters into a definitive agreement to acquire Poseida Therapeutics, including cell therapy candidates and related platform technologies

Acquisition supports Roche’s Pharma Strategy and allows for a range of potentially first and best-in-class therapies across oncology, immunology, and…

2 weeks ago